NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

MiNK Therapeutics, Inc. (INKT) Stock Analysis

MiNK Therapeutics, Inc. (INKT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INKT

$10.62

+$0.76 (+7.71%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INKT with… →

INKT Key Statistics

As of Oct 21, 2026
Trading
Open
$9.80
Previous Close
$9.86
Day's Range
9.80–10.99
52-Week Range
8.48–16.93
Volume
18.61K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.47
Valuation
Market Cap
$54.19M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.39
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.49M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.10M
1-Year Return
−28.58%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
13.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INKT closed at $10.62, −28.58% over 1 year.

MiNK Therapeutics, Inc. (INKT) has a market capitalization of $54.19M.

In fiscal 2025, INKT reported revenue of $0.00.

INKT Stock Return by Calendar Year

MiNK Therapeutics, Inc. (INKT) return since Oct 2021: what $10,000 became

1 year
$10,000 $7,142
−28.58%
5 years
$10,000 $844
−91.56%
Since Oct 2021
$10,000 $885
−91.15%

If you had invested $10,000 in MiNK Therapeutics, Inc. (INKT) at the close on October 15, 2021, the earliest close on record here, it would have been worth $885 at the close on October 21, 2026: −91.15% in total, −38.33% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.75%
2025+59.97%
2024−34.86%
2023−59.00%
2022−41.48%
2021 (partial year)−62.83%

As of October 21, 2026.

INKT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.49M—
2024$0.00−$10.78M—
2023$0.00−$22.46M—
2022$0.00−$27.99M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.49M−$12.49M—
2024$0.00—−$10.65M−$10.78M—
2023$0.00—−$22.92M−$22.46M—
2022$0.00—−$30.95M−$27.99M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values MiNK Therapeutics, Inc. (INKT) at $54.19M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 15.

Over the past 52 weeks the price has ranged from $8.48 to $16.93. The most recent close on file for INKT is $10.62, dated October 21, 2026. That is +$0.76 (+7.71%) against the previous close. The latest close sits 25.24% above that 52-week low.

Financial Health

In fiscal 2025, MiNK Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $12.49M. Earnings per share on a trailing basis come to −2.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is −28.58%. Across 5 years the annualized return works out at −39.02%. The reported beta is 0.47. Daily returns over the trailing 5 years annualize to a volatility of 347.64%.

Growth & Income

The record shows no dividend for INKT.

2026 is still running; the total return is −4.75% year to date. The strongest complete calendar year on file is 2025 at +59.97%; the weakest is 2023 at −59.00%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

MiNK Therapeutics, Inc. (INKT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MiNK Therapeutics, Inc. INKT $54.19M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. MiNK Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

Visit website →